Hosted on MSN1h
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity ...
Daily5h
Pfizer, AstraZeneca and several other drugmakers in race to join weight loss drug market
The drug, HS-10535, is a GLP-1 receptor agonist candidate similar to Wegovy and Zepbound. AstraZeneca's experimental ...
經濟通ET Net5h
{I-bank focus}CMB raises Hansoh Pharma (03692) to HKD25.24
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such ...